Literature DB >> 12080429

Participation of renal and circulating endothelin in salt-sensitive essential hypertension.

F Elijovich1, C L Laffer.   

Abstract

Salt sensitivity of blood pressure is a cardiovascular risk factor, independent of and in addition to hypertension. In essential hypertension, a conglomerate of clinical and biochemical characteristics defines a salt-sensitive phenotype. Despite extensive research on multiple natriuretic and antinatriuretic systems, there is no definitive answer yet about the major causes of salt-sensitivity, probably reflecting the complexity of salt-balance regulation. The endothelins, ubiquitous peptides first described as potent vasoconstrictors, also have vasodilator, natriuretic and antinatriuretic actions, depending on their site of generation and binding to different receptors. We review the available data on endothelin in salt-sensitive essential hypertension and conclude that abnormalities of renal endothelin may play a primary role. More importantly, the salt-sensitive patient may have blood pressure-dependency on endothelin in all states of salt balance, thus predicting that endothelin receptor blockers will have a major therapeutic role in salt-sensitive essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12080429     DOI: 10.1038/sj.jhh.1001419

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  6 in total

Review 1.  Inflammation and therapy for hypertension.

Authors:  Cheryl L Laffer; Fernando Elijovich
Journal:  Curr Hypertens Rep       Date:  2010-08       Impact factor: 5.369

Review 2.  The future of endothelin-receptor antagonism as treatment for systemic hypertension.

Authors:  Gabriel Vorobiof; Burns C Blaxall; John D Bisognano
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

3.  A potential role for the endothelin ETA receptor in salt-sensitive hypertension of the proANP gene-disrupted mouse.

Authors:  P F O'Tierney; E Angelis; M Y Tse; J J Pang; M A Adams; S C Pang
Journal:  Mol Cell Biochem       Date:  2005-07       Impact factor: 3.396

4.  Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment.

Authors:  Patricia N Sidharta; Ivan Ulč; Jasper Dingemanse
Journal:  Clin Drug Investig       Date:  2019-11       Impact factor: 2.859

5.  Role of 20-hydroxyeicosatetraenoic acid in mediating hypertension in response to chronic renal medullary endothelin type B receptor blockade.

Authors:  Joshua S Speed; Eric M George; Marietta Arany; Kathy Cockrell; Joey P Granger
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

6.  TRC120038, a Novel Dual AT(1)/ET(A) Receptor Blocker for Control of Hypertension, Diabetic Nephropathy, and Cardiomyopathy in ob-ZSF1 Rats.

Authors:  Anookh Mohanan; Ram Gupta; Amita Dubey; Vikrant Jagtap; Appaji Mandhare; Ramesh C Gupta; Vijay Chauthaiwale; Chaitanya Dutt
Journal:  Int J Hypertens       Date:  2011-12-22       Impact factor: 2.420

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.